| FDA approval summary: atezolizumab plus bevacizumab for the treatment of patients with advanced unresectable or metastatic hepatocellular carcinoma SJ Casak, M Donoghue, L Fashoyin-Aje, X Jiang, L Rodriguez, YL Shen, ... Clinical Cancer Research 27 (7), 1836-1841, 2021 | 153 | 2021 |
| Treatment of overt extraocular retinoblastoma G Chantada, A Fandiño, S Casak, J Manzitti, E Raslawski, E Schvartzman Medical and Pediatric Oncology: The Official Journal of SIOP—International …, 2003 | 143 | 2003 |
| FDA approval summary: pembrolizumab for the first-line treatment of patients with MSI-H/dMMR advanced unresectable or metastatic colorectal carcinoma SJ Casak, L Marcus, L Fashoyin-Aje, SL Mushti, J Cheng, YL Shen, ... Clinical Cancer Research 27 (17), 4680-4684, 2021 | 133 | 2021 |
| Nasopharyngeal carcinoma in childhood and adolescence: a single‐institution experience with combined therapy PA Zubizarreta, G D'Antonio, E Raslawski, G Gallo, MV Preciado, ... Cancer 89 (3), 690-695, 2000 | 111 | 2000 |
| FDA Approval Summary: Ramucirumab for Gastric Cancer. PR Casak SJ, Fashoyin-Aje I, Lemery SJ, Zhang L, Jin R, Li H, Zhao L, Zhao H ... Clin Cancer Res 21 (15), 3372-6, 2015 | 105 | 2015 |
| Results of a prospective study for the treatment of retinoblastoma G Chantada, A Fandiño, MTG Dávila, J Manzitti, E Raslawski, S Casak, ... Cancer 100 (4), 834-842, 2004 | 93 | 2004 |
| Children with fever of unknown origin in Argentina: an analysis of 113 cases G Chantada, S Casak, JD PLATA, J Pociecha, R Bologna The Pediatric infectious disease journal 13 (4), 260-263, 1994 | 92 | 1994 |
| FDA Approval Summary: Nivolumab Plus Ipilimumab for the Treatment of Patients with Hepatocellular Carcinoma Previously Treated with Sorafenib MT Saung, L Pelosof, S Casak, M Donoghue, S Lemery, M Yuan, ... The oncologist 26 (9), 797-806, 2021 | 89 | 2021 |
| Experience with chemoreduction and focal therapy for intraocular retinoblastoma in a developing country GL Chantada, AC Fandino, EC Raslawski, J Manzitti, MTG de Dávila, ... Pediatric blood & cancer 44 (5), 455-460, 2005 | 67 | 2005 |
| Retinoblastoma with low risk for extraocular relapse GL Chantada, MTG de Dávila, A Fandiño, J Manzitti, E Raslawski, ... Ophthalmic genetics 20 (3), 133-140, 1999 | 55 | 1999 |
| Activity of topotecan in retinoblastoma GL Chantada, AC Fandiñ, SJ Casak, G Mato, J Manzitti, E Schvartzman Ophthalmic genetics 25 (1), 37-43, 2004 | 54 | 2004 |
| US Food and Drug Administration approval: rituximab in combination with fludarabine and cyclophosphamide for the treatment of patients with chronic lymphocytic leukemia SJ Casak, SJ Lemery, YL Shen, MD Rothmann, A Khandelwal, H Zhao, ... The Oncologist 16 (1), 97-104, 2011 | 46 | 2011 |
| FDA approval summary: ivosidenib for the treatment of patients with advanced unresectable or metastatic, chemotherapy refractory cholangiocarcinoma with an IDH1 mutation SJ Casak, S Pradhan, LA Fashoyin-Aje, Y Ren, YL Shen, Y Xu, ... Clinical Cancer Research 28 (13), 2733-2737, 2022 | 45 | 2022 |
| Hodgkin disease in children: results of a prospective randomized trial in a single institution in Argentina F Sackmann‐Muriel, P Zubizarreta, G Gallo, M Scopinaro, D Alderete, ... Medical and Pediatric Oncology: The Official Journal of SIOP—International …, 1997 | 44 | 1997 |
| Phase II window of idarubicin in children with extraocular retinoblastoma GL Chantada, A Fandiño, G Mato, S Casak Journal of clinical oncology 17 (6), 1847-1847, 1999 | 39 | 1999 |
| FDA's approval of the first biosimilar to bevacizumab SJ Casak, SJ Lemery, J Chung, C Fuchs, SJ Schrieber, ECY Chow, ... Clinical Cancer Research 24 (18), 4365-4370, 2018 | 36 | 2018 |
| Paediatric oncology in Argentina: medical and ethical issues MJ Scopinaro, SJ Casak The lancet oncology 3 (2), 111-117, 2002 | 35 | 2002 |
| The Majority of Expedited Investigational New Drug Safety Reports Are Uninformative KS Jarow JP, Casak S, Chuk M, Ehrlich LA Clin Cancer Res., 2016 | 30 | 2016 |
| Acute myelogenous leukemia in Down's syndrome: report of a single pediatric institution using a BFM treatment strategy P Zubizarreta, MS Felice, E Alfaro, L Fraquelli, S Casak, R Quinteros, ... Leukemia research 22 (5), 465-472, 1998 | 30 | 1998 |
| Benefit‐risk summary of regorafenib for the treatment of patients with advanced hepatocellular carcinoma that has progressed on sorafenib L Pelosof, S Lemery, S Casak, X Jiang, L Rodriguez, V Pierre, Y Bi, J Liu, ... The Oncologist 23 (4), 496-500, 2018 | 21 | 2018 |
